Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATHIRA PHARMA, INC.

(ATHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Relatively Flat Premarket Friday

10/22/2021 | 08:56am EST


ę MT Newswires 2021
All news about ATHIRA PHARMA, INC.
11/10Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update - Form 8..
PU
11/10ATHIRA PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/10ATHIRA PHARMA, INC. : Results of Operations and Financial Condition, Regulation FD Disclos..
AQ
11/10Athira Pharma, Inc. Reports Earnings Results for the Third Quarter Ended September 30, ..
CI
11/10Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
GL
11/10Athira Pharma Discloses Update From Trials of ATH-1017 For Alzheimer's Disease Treatmen..
MT
11/10Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 i..
AQ
11/10Athira Pharma Presents Overview and Update from Act-Ad and Lift-Ad Trials of Ath-1017 i..
CI
11/08Athira Pharma to Present at Upcoming Investor Conferences
GL
10/29Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
GL
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -60,1 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -7,63x
Yield 2021 -
Capitalization 462 M 462 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 21
Free-Float 95,0%
Chart ATHIRA PHARMA, INC.
Duration : Period :
Athira Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATHIRA PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 12,38 $
Average target price 39,67 $
Spread / Average Target 220%
EPS Revisions
Managers and Directors
Mark J. Litton President & Chief Executive Officer
Glenna Mileson Chief Financial Officer & Secretary
Kelly A. Romano Chairman
Hans Moebius Chief Medical Officer
Xue Hua Vice President-Clinical Development Research
Sector and Competitors
1st jan.Capi. (M$)
ATHIRA PHARMA, INC.-63.85%462
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625